As of September 30, 2024, the Company had cash and cash equivalents of $8.0 million. The Company believes it has sufficient cash to fund its currently planned operations through the first quarter of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio announces first subject dosed in Phase 1 study of PALI-2108
- Palisade Bio announces data from two ex vivo studies of PALI-2108
- Palisade Bio files to sell common stock, warrants, no amount given
- Palisade Bio received No Objection Letter from Health Canada for Phase 1 study
- Palisade Bio CEO Finley’s Revised Employment and Compensation Deal